Grace and Formac Announce Positive Data from Clinical Trial Demonstrating Use of Silica for Drug Delivery

12:04 AM MDT | April 24, 2012 | Deepti Ramesh

W. R. Grace, in partnership with Formac Pharmaceuticals (Heverlee, Belgium), announced positive data from initial human studies of the companies' mesoporous silica-based drug delivery technology. This was the first-ever clinical study to demonstrate the bioavailability enhancing properties of silica in humans, Grace says. Improved bioavailability enables active pharmaceutical ingredients (API's) to more effectively absorb into the body. This technology opens up a viable new avenue for the development of poorly soluble compounds, Grace says. The bioavailability...